Repare Therapeutics Inc. (RPTX)
Market Cap | 137.52M |
Revenue (ttm) | 97.86M |
Net Income (ttm) | -45.69M |
Shares Out | 42.45M |
EPS (ttm) | -1.10 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 93,194 |
Open | 3.310 |
Previous Close | 3.330 |
Day's Range | 3.200 - 3.330 |
52-Week Range | 2.980 - 13.850 |
Beta | 0.73 |
Analysts | Strong Buy |
Price Target | 17.33 (+434.88%) |
Earnings Date | Aug 7, 2024 |
About RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treat... [Read more]
Financial Performance
In 2023, RPTX's revenue was $51.13 million, a decrease of -61.21% compared to the previous year's $131.83 million. Losses were -$93.80 million, 222.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for RPTX stock is "Strong Buy." The 12-month stock price forecast is $17.33, which is an increase of 434.88% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/s/d/press4-2497645.jpg)
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI.
![](https://cdn.snapi.dev/images/v1/d/1/press9-2475169.jpg)
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib
BOSTON--(BUSINESS WIRE)--Foundation Medicine announces a collaboration with Repare Therapeutics to provide genomic profiling for Repare's ongoing Phase I/Ib MYTHIC study.
![](https://cdn.snapi.dev/images/v1/f/i/press11-2470708.jpg)
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patien...
![](https://cdn.snapi.dev/images/v1/g/q/press18-2462476.jpg)
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food an...
![](https://cdn.snapi.dev/images/v1/4/1/conf4-2460027.jpg)
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of ...
![](https://cdn.snapi.dev/images/v1/p/z/conf18-2451204.jpg)
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the ...
![](https://cdn.snapi.dev/images/v1/e/h/press7-2416213.jpg)
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...
![](https://cdn.snapi.dev/images/v1/2/q/press18-2399334.jpg)
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debioph...
![](https://cdn.snapi.dev/images/v1/u/w/press19-2399335.jpg)
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
LAUSANNE, Switzerland & MONTREAL--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure ca...
![](https://cdn.snapi.dev/images/v1/m/p/press12-2395209.jpg)
Repare Therapeutics Appoints Steven H. Stein, M.D.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment ...
![](https://cdn.snapi.dev/images/v1/n/4/press18-2335477.jpg)
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $RPTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repar...
![](https://cdn.snapi.dev/images/v1/p/n/press20-2319093.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such investors are advise...
![](https://cdn.snapi.dev/images/v1/6/8/press18-2309110.jpg)
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTX
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning poss...
![](https://cdn.snapi.dev/images/v1/o/2/conf18-2300727.jpg)
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of ...
![](https://cdn.snapi.dev/images/v1/h/i/press6-2299601.jpg)
ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning ...
![](https://cdn.snapi.dev/images/v1/r/f/press4-2298036.jpg)
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results...
![](https://cdn.snapi.dev/images/v1/o/0/press13-2296642.jpg)
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTX
NEW YORK, NY / ACCESSWIRE / February 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Repare Therapeutics Inc. ("Repare Therapeutics") (NASDAQ:RPTX) concerning ...
![](https://cdn.snapi.dev/images/v1/g/d/press2-2281244.jpg)
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
NEW YORK--(BUSINESS WIRE)---- $RPTX #ClassActionLawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPT...
![](https://cdn.snapi.dev/images/v1/w/r/press15-2277728.jpg)
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patien...
![](https://cdn.snapi.dev/images/v1/t/w/press2-2272288.jpg)
Repare Therapeutics to Regain Global Rights to Camonsertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will reg...
![](https://cdn.snapi.dev/images/v1/k/a/press12-2244090.jpg)
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that, under its ...
![](https://cdn.snapi.dev/images/v1/z/b/press7-2219859.jpg)
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate updat...
![](https://cdn.snapi.dev/images/v1/v/v/press2-2217306.jpg)
Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
LAUSANNE, Switzerland & MONTREAL--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure ca...
![](https://cdn.snapi.dev/images/v1/b/g/press13-2217288.jpg)
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
MONTREAL & LAUSANNE, Switzerland--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has...
![](https://cdn.snapi.dev/images/v1/k/4/press18-2211785.jpg)
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthe...